1371 results

Certara to Participate in Upcoming Investor Conferences

PRINCETON, N.J.— May 3, 2022 — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conferences: Bank of America 2022 Healthcare ConferenceDate and Time: Tuesday, May 10 at 3:00 p.m. ET Citi’s Biopharma Virtual Co-Panel DayDate and Time: Wednesday, May 18 at 10:00 a.m. … Continued


Certara Wins 2022 Edison Award for COVID-19 Vaccine Model

PRINCETON, N.J., May 3, 2022 — Certara, Inc., a global leader in biosimulation, today announced that the Company’s Simcyp COVID-19 Vaccine Model has been awarded a 2022 Bronze Edison Award in the Therapeutic Impact category. The Simcyp COVID-19 Vaccine Model, which is incorporated in Certara’s Vaccine Simulator, uses biosimulation and computer-generated, virtual populations to facilitate … Continued


PAGE 2022

Exhibit spaces #2, 3


Simulating Realistic Virtual Bioequivalence using Simcyp Simulator: Estimating Within-subject Patient Variability

While using physiologically-based pharmacokinetic modeling (PBPK) in determining virtual bioequivalence (VBE) has significantly increased over the past few years, this type of mechanistic biosimulation still offers enormous potential to supplant expensive and time-consuming clinical studies. The paper referenced below addresses our increased knowledge of oral drug absorption and the applicability of the Simcyp Simulator to … Continued


Certara and Chemaxon Announce Collaboration in Scientific Informatics Software

PRINCETON, N.J., April 26, 2022 — Certara, Inc., a global leader in biosimulation, and Chemaxon, a leading chemical and biological software development company, today announced a strategic partnership to accelerate drug discovery research through integrated scientific informatic workflows to modernize pharmaceutical research. This partnership provides interconnectivity between Certara’s D360 Scientific Informatics software and Chemaxon’s Design … Continued


Reflections on the New FDA Clinical Pharmacology Guidance for Antibody-Drug Conjugates

The new Clinical Pharmacology Considerations for Antibody-Drug Conjugates (ADC), Guidance for Industry, was issued by the US Food and Drug Administration (FDA) in February 2022. ADCs are targeted therapies that are designed to deliver cytotoxic payloads to cancer cells. The cytotoxic payload is attached to a monoclonal antibody (that is designed for binding to the … Continued

2 of 138
Back to top